Device Wound Cleanser

Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap

Payments companies reported to CMS as associated with Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$610Kassociated payments (2023-2025)
3,976clinicians with associated payments
1company reporting

By year

2023 $221K
2024 $223K
2025 $166K

Payments reported as associated with Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Family $157K
Plastic and Reconstructive Surgery $89K
Plastic Surgery $60K
Foot & Ankle Surgery $46K
Adult Health (Nurse Practitioner) $39K
Surgery $31K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap

These are the largest totals companies reported as associated with Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Amanda Murray Great Falls, MT Family $62,292.56
Abigail Chaffin New Orleans, LA Plastic Surgery $44,438.42
Michael Desvigne Glendale, AZ Plastic and Reconstructive Surgery $43,661.00
Kara Couch Washington, DC Family $35,277.17
Elizabeth Faust Douglassville, PA Adult Health (Nurse Practitioner) $32,821.33
Kathy Gallagher Newark, DE Family $25,579.64
Mark Suski Thousand Oaks, CA Plastic and Reconstructive Surgery $17,058.55
Andrea Dunkelman Santa Ana, CA Plastic and Reconstructive Surgery $15,171.40
Paul Kim Dallas, TX Foot & Ankle Surgery $14,729.31
Shishir Shah Phoenix, AZ Family Medicine $8,840.56

Prescribed Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.